G&A

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
Mercredi, avril 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Dundee Corporation Renews Normal Course Issuer Bids on Three Share Classes

Retrieved on: 
Mardi, avril 9, 2024
G&A, Toronto Stock Exchange, Dundee Corporation, Security (finance), TSX, Security, Calendar, Mining

Reducing the number of Series 2 Shares and Series 3 Shares outstanding also lowers future dividend payments.

Key Points: 
  • Reducing the number of Series 2 Shares and Series 3 Shares outstanding also lowers future dividend payments.
  • As of March 31, 2024, Dundee had 85,711,707 Class A Shares, 1,145,362 Series 2 Shares and 724,982 Series 3 Shares issued and outstanding.
  • Under Dundee’s current normal course issuer bids which are set to expire on April 11, 2024, the Company sought and received approval from the TSX to purchase up to 7,571,650 Class A Shares, 114,916 Series 2 Shares and 181,752 Series 3 Shares.
  • The Company purchased a total of 246,400 Class A Shares at an average price of $0.82, 3,800 Series 2 Shares at an average price of $18.92 and 178,500 Series 3 Shares at an average price of $20.00 under the current normal course issuer bids.

The Simply Good Foods Company Reports Fiscal Second Quarter 2024 Financial Results and Updates Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook

Retrieved on: 
Jeudi, avril 4, 2024
Health, Convenience, Growth, EPS, Tax, International, Internet, Acquisition, G&A, Depreciation, Adjustment, IRI, Investment, Interest, GAAP, Earnings per share, Marketing, Advertising, Bookkeeping

"Simply Good Foods second quarter results were led by continued Quest growth, as well as strong gross margin performance," said Geoff Tanner, President, and Chief Executive Officer of Simply Good Foods.

Key Points: 
  • "Simply Good Foods second quarter results were led by continued Quest growth, as well as strong gross margin performance," said Geoff Tanner, President, and Chief Executive Officer of Simply Good Foods.
  • In the second quarter of fiscal 2024, total Simply Good Foods retail takeaway in the combined U.S. measured and unmeasured channels increased about 3%.
  • Year-to-Date Second Quarter 2024 Highlights vs. Year-to-Date Second Quarter 2023(1)
    Net sales increased $23.4 million, or 3.9%, to $620.9 million.
  • Due to lower than anticipated Atkins consumption in the second quarter of fiscal 2024, the Company has updated its full year fiscal 2024 outlook.

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Jeudi, avril 4, 2024
Research, Virtual, NSCLC, Immunotherapy, TIL, Patient, G&A, Allele, ACHL, HLA, Neoplasm, Therapy, Event, Safety, Melanoma, Patent, Escape Room, Cryptocurrency

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Key Points: 
  • These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
  • Research and development (R&D) expenses: R&D expenses were $15.9 million for the fourth quarter ended December 31, 2023, a decrease of $3.0 million compared to $18.9 million for the fourth quarter ended December 31, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $3.6 million for the fourth quarter ended December 31, 2023, a decrease of $0.4 million compared to $4.0 million for December 31, 2022.
  • Net loss: Net loss for the fourth quarter ended December 31, 2023 was $18.6 million or $0.46 per share compared to $24.1 million or $0.61 per share for the fourth quarter ended December 31, 2022.

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Retrieved on: 
Mardi, avril 2, 2024
Research, Frost, Patent, Partnership, Patient, OUD, G&A, Opioid use disorder, Addiction, GLEN, Consultant, Pharmaceutical industry

GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.

Key Points: 
  • GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
  • Specifically, we conducted meetings and received favorable feedback from both US and European regulators, allowing us to refine our clinical development plan.
  • Cash and cash equivalents were $2.8 million as of December 31, 2023, compared to $4.0 million as of December 31, 2022.
  • Net Loss was $5.1 million for the year ended December 31, 2023, compared to a net loss of $12.7 million for the year ended December 31, 2022.

Abivax reports 2023 financial results and operational update

Retrieved on: 
Mardi, avril 2, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Aura Reports Updated Mineral Reserves and Mineral Resources

Retrieved on: 
Mardi, avril 2, 2024
QA/QC, OP, PGO, GHZ, Independent, Confederation, KGEO, Copper, Sale, G&A, Geology, Disclosure, Investment, Quality assurance, LOM, Marketing, Jacobs Solutions, Silver, Aura Minerals, Technical, Arsenic, Quality control, Feasibility study, Measurement, Anomaly, NW, GEO, Technical report, MRMR, Qualified person (European Union), Federal Road, Municipality, Radius, Mineral Resources Limited, TSX, XMobots Apoena, Dowdell, Soil, ROAD, Net smelter return, Mining, HLP, SRK, Growth, EPP, Gold, Metal, NSR, Table, Life, Call, Consultant, Resource, Uranium mining

The charts below show changes in P&P Mineral Reserves, M&I Mineral Resources and Inferred Mineral Resources for the Aranzazu Mine as of December 31, 2023 compared to December 31, 2022.

Key Points: 
  • The charts below show changes in P&P Mineral Reserves, M&I Mineral Resources and Inferred Mineral Resources for the Aranzazu Mine as of December 31, 2023 compared to December 31, 2022.
  • The charts below show changes in P&P Mineral Reserves Estimates, M&I Mineral Resources Estimates and Inferred Mineral Resources Estimates for Apoena as of December 31, 2023, compared to December 31, 2022.
  • Mineral Reserves estimated by Aura total approximately 34.5 Mt in P&P Mineral Reserves at an average grade of 0.50 g/t Au.
  • Borborema also showcases a strong Mineral Reserve base, with Probable Mineral Reserves of 812,000 oz gold, and an extensive Mineral Resource profile with strong growth potential that consists of 2,077 koz of indicated Mineral Resources and 393 koz of Inferred Mineral Resources.

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Retrieved on: 
Lundi, avril 1, 2024
Research, Court of Chancery, Notifiable disease, Ovarian cancer, JAMS, Prejudice, District court, Inflammation, Patient, Sale, News, G&A, University, Cancer, Trial of the century, Bank statement, Loss, Complaint, Pancreatic cancer, Patent, Probability, Court, Pharmaceutical industry

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
  • Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “These are exciting times at HCW Biologics.
  • Revenues: Revenues for the fourth quarters ended December 31, 2022 and 2023 were $1.3 million and $1.3 million, respectively.
  • Net loss: Net loss for the fourth quarters ended December 31, 2022 and 2023 were $5.4 million and $10.7 million, respectively.

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Lundi, avril 1, 2024
FC, TME, Administration, Cell, Partnership, Patient, Gilead Sciences, Pharming, Research, Tumor microenvironment, G&A, Cancer, PacWest Bancorp, AACR, MSS, Investment, Therapy, CRC, Safety, Workforce, PD-1, Pharmaceutical industry

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) --  Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Xilio today reaffirmed plans to:
    Select a recommended Phase 2 dose for XTX101 in combination with atezolizumab in the second quarter of 2024.
  • In March 2024, Xilio and Gilead Sciences, Inc. (Gilead) announced an exclusive license agreement for Xilio’s tumor-activated IL-12 program, including XTX301.
  • Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales.
  • Net Loss: Net loss was $17.7 million for the quarter ended December 31, 2023, compared to $22.5 million for the quarter ended December 31, 2022.

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Lundi, avril 1, 2024
Diagnosis, Research, Week, CD135, Administration, FMS, Growth, Menin, CLL, NSCLC, C-peptide, AML, BID, Diabetes, Insulin, Patient, Hypoglycemia, FLT3, G&A, Acute myeloid leukemia, Food, PDAC, Health Canada, Trial of the century, IND, Cancer, CRC, Safety, Research and development, Investment, FDA, DLBCL, DSM-IV codes, Pharmaceutical industry

In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.

Key Points: 
  • In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024.
  • Cash position of $177.2 million at the end of the fourth quarter of 2023.
  • REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported fourth quarter and full year 2023 financial results and corporate highlights.
  • “2023 was a pivotal year for Biomea as we reported first positive data in type 2 diabetes and initiated our first clinical study in type 1 diabetes.